

1 Bi-allelic variants in RNF170 cause hereditary spastic  
2 paraplegia

3 - Supplementary Material –

4

5 **Supplementary methods**

6

7 **Supplemental information on variant annotation methods**

8 **Family A** - Genome sequencing of both affected siblings from Family A (A.4, A.5) was  
9 performed using Truseq PCR-free sample preparation (Illumina), followed by sequencing on  
10 a HiSeq X HD v2.5 instrument (Illumina). More than 1,684,998,067 reads with an average  
11 read length of 150bp were produced. Data was processed and analysed using the Genesis  
12 pipeline<sup>1</sup>. 99.77% of reads could be mapped to the UCSC human reference assembly (hg19);  
13 the average read depth was 34.75.

14 **Family B** - Exome sequencing of one affected sibling (B.4) was performed using the Agilent  
15 SureSelect All Exon V6 kit (Agilent) and a HiSeq 2500 (Illumina) platform. Reads were  
16 aligned to the human reference genome (UCSC hg19), with Burrows-Wheeler Aligner  
17 (BWA,V.0.7.8-r455)<sup>2</sup>. High quality indel and single nucleotide variant calling and annotation  
18 were performed using GATK v3.1 using standard filtering criteria (read depth  $\geq 10\%$ ,  
19 genotype quality score  $\geq 50$ ).<sup>2</sup> Candidate genes were prioritized by searching for  
20 homozygous variants with a minor allele frequency  $< 0.1\%$  in 1000 in-house ethnically-  
21 matched Iranian control exomes, dbSNP, 1000 Genomes and ExAC.

22 **Family C** - Trio-Exome sequencing of the index case and his parents (C.1, C.2, C.4) was  
23 performed using a Sure Select Human All Exon 60Mb V6 Kit (Agilent) for enrichment and  
24 the HiSeq4000 (Illumina) platform for sequencing. An average of 135,888,843 reads were  
25 produced per sample and aligned to the UCSC human reference assembly (hg19) with BWA  
26 v.0.5.8.1 More than 98% of the exome was covered at least  $20\times$  and the average coverage was

27 more than 126×. Single-nucleotide variants (SNVs) and small insertions and deletions were  
28 detected with SAMtools v.0.1.7. Copy number variations (CNVs) were detected with  
29 ExomeDepth<sup>3</sup> and Pindel<sup>4</sup>. Variant prioritization was performed based on an autosomal  
30 recessive (MAF <0.1%) and autosomal dominant (*de novo* variants, MAF <0.01%)  
31 inheritance model.

32 **Family D** – Duo exome sequencing of both affected siblings (D.3, D.4) was done using an  
33 xGen Exome Research Panel v1.0 for targeted enrichment and a HighSeq 4000 sequencing  
34 platform (Illumina). The sequence reads were aligned to the reference genome, hg19, using  
35 BWA MEM and underwent duplicate removal (Picard v2.5.0), indel realignment and base  
36 quality realignment (GATK) and variant calling (HaplotypeCaller) as recommended in the  
37 GATK Best Practices<sup>5</sup>. The detected variants were annotated by ANNOVAR<sup>6</sup>. Variants were  
38 filtered to consider only homozygous SNVs and short Indels due to their higher probability of  
39 contribution to the disease in this consanguineous family.


40

41 **Supplementary Figures**

**Experimental setup of breakpoint PCR**



**Screening in Tunisian HSP index patients**




42

43 **Supplementary Figure 1:** Screening for the chr8:g .42,704,626\_42,729,012delinsTTTTGGT

44 mutation in 34 Tunisian HSP index patients of unknown genetic etiology.

45



46


47 **Supplementary Figure 2: Fundoscopy and optical coherence tomography (OCT) of**

48 **patient A.4.** Color fundus photography shows mild paleness of the optic nerve head in the

49 temporal sector on both eyes; OCT reveals temporal optic nerve atrophy on both eyes, but

50 otherwise unremarkable retinal structures, in particular no chorioretinal atrophy.

51



52

53 **Supplementary Figure 3:** Alignment of zebrafish *rnf170* coding region with human  
 54 *RNF170*. Black highlighted nucleotides indicate regions of homology, red bars mark exon  
 55 boundaries, and red boxes indicate patient mutations.

56




57

58 **Supplementary Figure 4:** Alignment of zebrafish Rnf170 protein with human RNF170.

59 Black highlighted amino acids indicate regions of homology, red bars mark exon boundaries,

60 and a red box indicates the patient missense mutation p.Cys102Arg.

61




62

63 **Supplementary Figure 5:** Validation of targeted *rnf170* knockdown by antisense morpholino  
 64 injections into zebrafish embryos followed by RT-PCR. (a) Schematic representation of the  
 65 two-morpholino target sites (E3MO and E4MO, red bars). Primer sets were designed to  
 66 validate either E3MO (primers: E2F, I2R, E3R. Blue arrows) or E4MO (primers: E3F, I3R,  
 67 E4R. Black arrows) by RT-PCR. (b) RT-PCR performed on 48 hpf *rnf170* morphant or

68 control morphant embryos (con). Injections of E3MO causes inappropriate splicing of intron  
69 2 and predicted premature stop, as indicated by the presents of an expected 226 bp amplicon  
70 in the E3MO lane, compared to its absence in the con lane (primer pair E2F;I2R).  
71 Concurrently, amplification using exonic primers (E2F:E3R) results in the expected amplicon  
72 of 196 bp in only the con embryos, compared to multiple additional larger products found in  
73 the E3MO lane. Similarly, injections of E4MO results in the inclusion of intron 3 and  
74 predicted premature stop, as indicated by the presents of an expected 169 bp product (primer  
75 pair E3F;I3R) in the rnf170 morphant samples compared to its absence in con embryos.  
76 Amplification using exonic primers (E3F:E4R) shows an expected amplicon at approximately  
77 158 bp in control embryos but an additional larger product in the E4MO injected embryos,  
78 indicative of the intronic inclusion. Amplification of a 300bp GAPDH amplicon was used as a  
79 positive control. (c) Quantification of morpholino efficacy by measuring the relative amplicon  
80 intensity between expected exonic amplicons (E2F:E3R, E3F:E4R) from control morpholino  
81 injected embryos verses morphants. Each band was normalized against GAPDH before  
82 relative intensity against control was calculated.

83





84

85 **Supplementary Figure 6: *rnf170* is expressed in the developing brain and intersomitic regions**

86 **and *rnf170* knockdown affects motorneuron development.** (a) Top two panels show lateral and

87 dorsal views, respectively, of a representative 48 hpf embryo stained using an antisense probe against

88 *rnf170* transcript. The two bottom panels show lateral and dorsal views, respectively, of a

89 representative 48 hpf embryo stained using a sense control probe against *rnf170*. Scale bar: 200  $\mu$ m.

90 (b) Staining for acetylated tubulin in larvae 48 hpf shows disorganized caudal primary motorneurons


91 in *rnf170* knockdown embryos. Localisation of antigen signal appeared punctate and intermittent in

92 *rnf170* morphants compared to controls (arrows). Scale bar represents 100  $\mu$ m. (c) At 4dpf *rnf170*

93 morphant verses control MO injected embryos continue to show reduced motorneuron staining in the

94 myotome, whilst acetylcholine receptors (AchR) persists. Motorneurons (arrows) are stained using

95 acetylated Tubulin (red), AchR are marked using bungarotoxin (green). Scale bar represents 100  $\mu$ m.



96

97 **Supplementary Figure 7: *rnf170* knockdown at the translational recognition start site**

98 **results in a similar phenotype to *rnf170* splice morphants. (a) *rnf170* AUG morphants**

99 display shortened body axis, microphthalmia (arrows), microcephaly (brackets) and alterations


100 in pigmentation (arrow heads). Scale bar represents 500  $\mu\text{m}$ . (b) Staining for the axonal

101 marker acetylated tubulin at 48 hpf (arrow heads), *rnf170* AUG morphants display punctate

102 and intermittent antigen localisation when compared to control MO injected embryos. Scale

103 bar represents 100  $\mu\text{m}$ .

104



105

106 **Supplementary Figure 8:** (a) Sanger sequencing confirms presence of a 35bp deletion in the  
 107 RNF170 gene that was introduced by a CRISPR/Cas9 approach. (b)-(c) SH-  
 108 SY5Y(RNF170<sup>ko</sup>) cells were stably transfected with RNF170 constructs carrying RNF170  
 109 mutations.

110

111 **Supplementary Tables**

112 **Supplementary Table 1: Variants in RNF170 identified in the present study**

family	genomic variant (hg19)	zygosity	cDNA	protein effect	mutation type	gnomAD alleles
<i>A</i>	chr8:42720556T>C	hom	NM_030954.3: c.396+3A>G	p.Ala109Asnfs*9	splice	1/245854
<i>B</i>	chr8:42725165A>G	hom	NM_030954.3: c.304T>C	p.Cys102Arg	missense	1/246108
<i>C</i>	chr8:42704626_42729012delinsTTTTGGT	hom	c.? [delEx4_7]	p.?	CNV	absent
<i>D</i>	chr8:42711560_42711561delTC	hom	NM_030954.3: c.518_519delAG	p.Arg173Asnfs*49	deletion	absent

113

114

115 **Supplementary Table 2: Information on exome sequencing and bioinformatics pipelines**

<b>Fa</b>	<b>Sequen</b>	<b>Sequenc</b>	<b>Instrum</b>	<b>Experim</b>	<b>Library/</b>	<b>Reads</b>	<b>Mapped reads</b>	<b>% Mapped</b>	<b>Mean</b>	<b>Covera</b>	<b>alignm</b>	<b>variant</b>
<b>m-</b>	<b>ced</b>	<b>ing</b>	<b>ent</b>	<b>ent type</b>	<b>Exome</b>				<b>coverag</b>	<b>ge 20X</b>	<b>ent</b>	<b>caller</b>
<b>ID</b>	<b>individu</b>	<b>center</b>			<b>capture</b>				<b>e</b>		<b>tool</b>	
	<b>als</b>											
<b>A</b>	A.4, A.5	Hudson Alpha (Huntsvil le, Alabama )	Illumina HiSeq X HD v2.5	WGS	TruSeq DNA PCR-Free Library Prep	870,404,738 (A.4) / 814,593,329 (A.5)	868,079,887 (A.4) / 812,703,476 (A.5)	99.73 (A.4) / 99.77 (A.5)	34.90 (A.4) / 34.60 (A.5)	95.5% (A.4) / 93.0% (A.5)	BWA v.0.7.1.2	Freebayes
<b>B</b>	B.4	Novoge ne (Beijing, China)	Illumina HiSeq 2500	WES	Agilent SureSelect Human All ExonV5/V6	44,055,430	43,991,117	99.85	99.9%	94.1%	BWA v.0.7.8- r455	GATK v3.1
<b>C</b>	C.1, C.2, C.4	Helmhol tz Center Munich, Germany	Illumina HiSeq 4000	WES (Trio)	Agilent SureSelect Human All Exon V6	118,305,358	118,076,733	99.81	126.51	98.16%	BWA v.0.5.8	SAMtools v.0.1.7, ExomeDept h, Pindel
<b>D</b>	D.3, D.4	Yale Center for Genome	Illumina HiSeq 4000	WES	IDT xGen® Exome Research	38,541,168(D.1)/41, 791,764 (D.2)	38,514,682(D.1)/41, 773,100 (D.2)	99.93% (D.1)/99.96% (D.2)	26.789(D .1)/ 29.024(D	95.8%/9 7%	BWA 0.7.12- r1039	GATK v3.6- 0- g89b7209

Analysis

Panel v1.0

.2)

HaplotypeC  
aller

---

116

117

Primer name	Sequence (5'→3')
<b>Primers for confirmation of gDNA variants (Fig. 1)</b>	
Fam A_F1	AGGAAGCTACGATCATGCCA
Fam A_R1	AAGGGTTGGCTGGATGAAGT
Fam B_F1	CGTTTACAGTTTGATGAGGGTTACA
Fam B_R1	TTGGTTGACAAGTAGAGCAGGAT
Fam C_F1	GCCAGTCAGTGGTGAGTGAG
Fam C_R1	GTCCATTGGCACCATTTTTTC
Fam C_F2	GAAAGAAGCCCATGTTTCCA
Fam C_R2	TTCACCCAGAAAACCAGGAG
Fam D_F1	GCCATGGGTCCTTCTGTTTG
Fam D_R1	CGCGCTAGGTTCTTTGGTTT
<b>Confirmation of splicing defect in Fam A (cDNA) (Fig. 1c)</b>	
Fam A_F_cDNA	CTTCAAACAGAACAGGATGCAC
Fam A_R_cDNA	GGGGGCCTTTTCTGGATGTT
<b>qRT-PCR primers (Fig. 1e)</b>	
RNF170_F	GGCAGTTGTGGTCAGTTTCG
RNF170_R	CAGGTGCATCCTGTTCTGTTTG
RNF10_F	CAC CCA CTG CCA GTC AGG GC
RNF10_R	TCC CCG TCG CTG TCC ACA GG
RNF111_F	GCAGAATGCAGCAGAAGTTG
RNF111_R	CCATTCTTGCAGAAGTGTTG
RPLPO_F	CCCGAGAAGACCTCCTTTTT
RPLPO_R	GGGTTGTAGATGCTGCCATT
<b>Confirmation of knockout in SH-SY5Y cells (Fig. 8a)</b>	
SH-SY5Y_F	GTGTTCCAATGTGTGCACCTG

SH-SY5Y_R	CCCAAGTATAGCGTTGTTTGCTT
<b>Confirmation of plasmid mutations (Fig. 8b+c)</b>	
plsmid_RNF170_F	GCCACTCGACAGCAGTTCTA
plsmid_RNF170_R	GGTCATCTAGTTAGCCTTTGGGT

120

121



122 **References**

123 1. Gonzalez M, Falk MJ, Gai X, Postrel R, Schule R, Zuchner S. Innovative genomic collaboration  
124 using the GENESIS (GEM.app) platform. *Hum Mutat* **36**, 950-956 (2015).  
125 2. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform.  
126 *Bioinformatics* **26**, 589-595 (2010).  
127 3. Plagnol V, *et al.* A robust model for read count data in exome sequencing experiments and  
128 implications for copy number variant calling. *Bioinformatics* **28**, 2747-2754 (2012).  
129 4. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect  
130 break points of large deletions and medium sized insertions from paired-end short reads.  
131 *Bioinformatics* **25**, 2865-2871 (2009).  
132 5. Van der Auwera GA, *et al.* From FastQ data to high confidence variant calls: the Genome  
133 Analysis Toolkit best practices pipeline. *Curr Protoc Bioinformatics* **43**, 11 10 11-33 (2013).  
134 6. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-  
135 throughput sequencing data. *Nucleic Acids Res* **38**, e164 (2010).  
136